Innovative approaches to funding for Scottish life sciences

Scottish Enterprise, Life Science Scotland and the BIA invite you to a day of masterclasses and networking on 16 May 2018 at the Hilton Glasgow (prior to the Scotland’s Life Sciences Dinner & Annual Awards 2018).

The workshops will focus on accessing both government and VC funding, and will feature speakers from key sources, and also from companies who have successfully raised funds discussing their experiences and sharing advice.  A networking lunch will be preceded by an update from the BIA, providing an overview of the current climate for biotech in the UK, and issues affecting innovative life science organisations.

Note - contact data will be shared with these organisations.

Date
Wednesday 16 May 2018
Venue
Hilton Glasgow
1 William St
Glasgow
3 8HT
Agenda

Morning session - Masterclass : R&D funding to support your growth

Scotland has an enviable reputation over centuries of pioneering invention and medical innovation. Life science companies operating in Scotland benefit from a wealth of support for business growth, including a variety of R&D grants.

Whether you are getting involved in R&D for the first time or looking to expand the research and development activities of your company, this event will advise you which grants are best for you.

  • Learn about SMART, R&D Grants and Innovation Support, and what makes a successful application.
  • Find out how the Knowledge Transfer Network can support you with applications to Innovate UK funding calls.
  • Bust the myths of what European Funding is available from Horizon 2020.

9.30                         Registration and coffee

10.00                     R&D Funding to support your growth                             

Andrew Henderson

Team Leader – High Value Manufacturing & Health

Scottish Enterprise

Andrew leads a team which works closely with industry, academic, healthcare and Government partners to develop and deliver strategies to support the growth of the Life & Chemical Sciences industry in Scotland, with a specific focus on manufacturing, medical devices, pharmaceutical services and regenerative medicine. Andrew has also worked with the Scottish Investment Bank, leading a programme to boost equity investment in Scottish companies. Prior to this, Andrew was Programme Leader for Scottish Enterprise's flagship Life Science project - the Edinburgh BioQuarter. In over 15 years at SE, he has been responsible for developing the Scottish Centre for Regenerative Medicine and the development of a national strategy for regenerative medicine with industry stakeholders. Andrew has been a director of Roslin Cells Ltd, a founder and Director of the Scottish Stem Cell Network, and a Director of Scottish Health Innovations Ltd – which works in partnership with NHS Scotland to protect and develop new innovations which come from NHS Scotland’s Health professionals.
Prior to Scottish Enterprise, Andrew spent over 10 years working for high-profile Scottish medical device startups, including Optos and Voxar (now Canon), in a variety of engineering, product development, marketing and management roles – working with some of the world’s biggest medical companies. Andrew has an MBA from the University of Edinburgh’s Business School.

10.05                    A New Approach to Innovation Support from Scottish Enterprise

Dr Paul Cross

Innovation Specialist

Scottish Enterprise

Paul Cross is an Innovation Specialist at Scottish Enterprise. As part of the role, Paul deals with all sizes of companies from pre-start-up to multi-nationals in all industrial sectors across Scotland. Paul evaluates many different types of projects which primarily focus on prototype development and proof of concept. These projects can often compliment, or be a precursor to, the bigger R&D projects. Applications are evaluated on novelty, degree of technical challenge and the positive impact they could have on the company (applicant), society and the economy. Also as part of the Innovation Specialist role, Paul can support businesses with guidance on innovation management, strategy and culture, as well as, benchmarking innovation performance against industry peers. Paul graduated from the University of Strathclyde in 2003 with a PhD in Chemistry, before occupying R&D, manufacturing and innovation roles for BASF, before becoming Head of R&D for a protective coatings company. Paul is excited to talk about any potential innovation projects that companies may have.

Andrew Ingram

Grant appraisal specialist

Scottish Enterprise

Andrew has worked as a grant appraisal specialist within the SMART/R&D grants team at Scottish Enterprise for the last four years, and prior to that spent five years working for an SME as R&D manager within the life sciences industry.
The SMART/R&D grants team at Scottish Enterprise work with companies across Scotland to advise on a range of potential funding mechanisms, identifying opportunities to help companies develop new or improved products, processes and services.

10.30                    Innovate UK grants                         

Jim Berryman, Knowledge Transfer Network

Michael Kipping

Innovation Lead

Innovate UK

Michael is an Innovation Lead for the Biomedical Catalyst funding programme at Innovate UK, the UK’s innovation agency. The Biomedical Catalyst has provided over £125m grant funding to innovative healthcare SMEs since 2012.
Michael joined the Medicines & Healthcare products Regulatory Agency (MHRA) as Group Manager for the Medical Devices Safety & Surveillance Group and led a team of ~40 engineers and scientists whose primary focus was patient safety. There are >500,000 individual medical devices in the UK including in-vitro diagnostics, hip replacements, wheelchairs, pacemakers, contact lenses and certain stand-alone software packages. No medical device is without risk and the team helped monitor the safety of devices and sought to work collaboratively with manufacturers and stakeholders to ensure that when issues arose, they were dealt with appropriately and promptly. The team were also heavily involved in the development of standards, future regulation and pre-market clinical investigations of non-CE marked medical devices.

11.00                    Horizon 2020 and other European opportunities                               

Liam Angus, Scottish Enterprise

11.30                     Q&A

12.00               BIA update

Dr Martin Turner

Policy and Projects Manager

BIA

Martin joined the BIA in April 2016 as Policy and Projects Manager. He is responsible for innovation policy and industrial strategy. He also provides the secretariat for the BIA’s Finance and Tax Advisory Committee and the Intellectual Property Advisory Committee.

Martin has 5 years’ experience in policy and public affairs and has worked at the Royal Society, the Campaign for Science and Engineering, and the Association of Medical Research Charities. Before embarking on a career in policy, Martin completed a PhD in molecular biology at the University of Sheffield, where he also co-founded and was director of an award-winning science communication charity called Science Brainwaves. He has a BSc in molecular biology from the University of Manchester.

                                Networking Lunch 

 

Afternoon session - Masterclass : Successful Life Sciences Fundraising

The UK has the strongest life science and health technology pipeline in Europe with more UK biotech companies maturing and successfully moving through the financing life cycle.    How can you be part of this success?

Scotland has a strong investment environment, with one of the most active early-stage investor networks in Europe and is second only to London in terms of the number of Life Sciences companies raising venture finance. The Scottish Investment Bank is one of the most active Life Sciences investor in the UK.

Whether you are looking for seed funding to start your business or wishing to resource your growth ambitions with venture funding, this event is for you.

  • Come and hear what venture investors are really looking for.
  • Learn about a selection of key life sciences venture capital funds.
  • Learn from the fundraising experience of successful Scottish companies.
  • Discover strategies to optimise your communications with investors

13.30                     Welcome                                

Norman Haque

Managing Director of Life Sciences

Silicon Valley Bank

Nooman Haque is the Managing Director of Life Sciences and Healthcare at Silicon Valley Bank’s UK Branch. He leads a team dedicated to supporting early, growth-stage and established multinational businesses in all sectors of life sciences. Nooman is responsible for expanding the bank’s business in this key sector and working with the global life sciences team to support companies with all aspects of their business, beyond financing. He is actively involved within the sector, sitting on the BIA’s Finance and Tax Committee and is a frequent panelist, writer and spokesperson for the industry.

Nooman joined Silicon Valley Bank from a venture capital firm in London and previously worked at a sovereign wealth fund in Saudi Arabia largely focused on healthcare. His background includes management consulting and corporate finance.

Nooman has a Bsc in psychology and an Msc in economics, both from the University of London, and an MBA (finance) from Imperial College.

13:35                   Fundraising -  a general introduction to being investor ready                               

Jonathan Lloyd-Hirst

Director

EY

Jonathan Lloyd-Hirst is a Director in EY’s life sciences Transaction Diligence team, based in Edinburgh and operates across the UK, Europe and beyond. Jonathan has led numerous projects in the life sciences sector with clients including large pharma, biotech, medtech, support services and PE/ VC. Jonathan’s experience includes buyside and sellside transactions, as well as IPOs. Jonathan also spent 18 months on secondment at the Scottish Investment Bank, leading a number of successful investments in the life sciences sector.

13.50                   Investment support from the Scottish Investment Bank     

Michelle Kinnaird

Investment Director

The Scottish Investment Bank

Michelle Kinnaird is the Investment Director in The Scottish Investment Bank (SIB), the investment arm of Scotland’s main economic development agency, Scottish Enterprise’s (SE), working in partnership with Highland and Islands Enterprise.

SIB ‘s role is to grow Scotland’s private sector funding market, ensuring both early stage and established SME’s with growth and exporting potential have adequate access to growth capital to reach their full potential.

SIB manages three funds – the Scottish Co-Investment Fund, the Scottish Venture Fund and the Renewable Energy Investment Fund; has invested in two externally managed funds; Epidarex Capital’s life sciences fund and the Scottish Loan Fund (now closed to new investments), which is privately managed by Maven Capital Partners and has developed a new funding mechanism in partnership with the European Investment Fund – the Scottish-European Growth Co-Investment Programme.

Michelle leads a team responsible for executing SE’s Investment transactions including SIB’s range of equity funds, is responsible for SE’s Scottish Loan Fund and European Investment Fund interest, the Renewable Energy Investment Fund and SIB’s Finance & Reporting Team. She has been the lead for SE in the establishment of the the Scottish-European Growth Co-Investment Programme.

14.00                  Panel Discussion: Fundraising lessons from successful Scottish companies

Chair: Nooman Haque, Silicon Valley Bank
Ian Stevens BioFilm
Deborah O’Neil, Novabiotics
Mike Leek, TC Biopharm

Dr Deborah O'Neil

Chief Executive Officer

NovaBiotics

A biotechnologist with two decades of experience in the field of anti-infectives research & drug development, Deborah studied immunology at University College London and then worked in internationally acclaimed laboratories in San Diego and Ghent before moving to Aberdeen. It was here where, in order to fully develop the commercial potential of her platform of novel antibacterial and antifungal therapies, she founded NovaBiotics in 2004. Deborah has since grown the business - as its Chief Executive & Scientific Officer - into a leading global biotechnology company with a portfolio of clinical-stage and preclinical anti-infective drug candidates for medically unmet infectious diseases. Deborah is editor of the European Biopharmaceutical Review and International Pharmaceutical Technology, a member of the Scottish Life Science Industry Leadership Group and sits on the Advisory Board of the Scottish Life Sciences Association. Deborah is also a member of the newly formed Life Sciences board of Opportunity North East and an elected Board Member of Aberdeen & Grampian Chamber of Commerce as well as being a proud Trustee of Crohn’s in Childhood Research Association.

Ian Stevens

BioFilm

Ian Stevens is a graduate of Edinburgh University, former Royal Air Force officer and chartered accountant who worked for KPMG in Oxford and Prague from 1991 to 1997.
Between 1998 and 2007 Ian was employed by Optos plc, a medical technology company specialising in the imaging of the retina, firstly in the role of CFO in Dunfermline, Scotland, and then from 2003 as General Manager, North America in Boston, USA.
From 2007 to 2010 Ian was CEO of Mpathy Medical, a surgical medical device company and in 2011 he joined prosthetic hand manufacturer, Touch Bionics, as CEO. Mpathy was sold to Danish surgical medical device manufacturer Coloplast in 2010 and Touch Bionics was sold to Icelandic Orthotic and Prosthetic manufacturer Ossur in 2016.

Mike Leek

TC Biopharm

Michael has 27 years’ experience in regenerative medicine, during which he progressed 9 different cell-based products from laboratory into clinic. As co-founder, he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. He has extensive GMP manufacture, clinical, regulatory and logistic expertise, he has directly raised over £50m in equity and grant funding.

14.45                 Panel discussion: What are Life Sciences VCs looking for?             

Chair: Michelle Kinnaird, Scottish Investment Bank
Nooman Haque, Silicon Valley Bank
Giovanni Mariggi, Medixci
Bill Blair, Bridge Valley Ventures   

Norman Haque

Managing Director of Life Sciences

Silicon Valley Bank

Nooman Haque is the Managing Director of Life Sciences and Healthcare at Silicon Valley Bank’s UK Branch. He leads a team dedicated to supporting early, growth-stage and established multinational businesses in all sectors of life sciences. Nooman is responsible for expanding the bank’s business in this key sector and working with the global life sciences team to support companies with all aspects of their business, beyond financing. He is actively involved within the sector, sitting on the BIA’s Finance and Tax Committee and is a frequent panelist, writer and spokesperson for the industry.

Nooman joined Silicon Valley Bank from a venture capital firm in London and previously worked at a sovereign wealth fund in Saudi Arabia largely focused on healthcare. His background includes management consulting and corporate finance.

Nooman has a Bsc in psychology and an Msc in economics, both from the University of London, and an MBA (finance) from Imperial College.

Dr Giovanni Mariggi

Principal

Medicxi

Vanni is a Principal in the Medicxi investment team with main focus on growth stage clinical opportunities. Prior to joining Medicxi, Giovanni was a Principal with Index Ventures, having joined the firm in 2012. Before that he was at Cancer Research UK's London Research Institute (LRI; now the Crick Institute). At the LRI he conducted research focused on vascular biology and angiogenesis, whilst also delivering competitive intelligence projects to biopharmaceutical companies in the oncology field. Giovanni currently sits on the board of directors of Gadeta, SuperX, Kymo Therapeutics and Janpix.
He obtained a BSc in Biochemistry from Imperial College London and a PhD in Biochemistry and Molecular Biology from University College London.

Bill Blair

Bill is a highly experienced adviser and investor in life sciences and related sectors. He is an Adviser to Bridge Valley Ventures, a new life sciences fund venture fund manager. He is also a member of the Investment Advisory Board of Alderley Park Ventures and a Non-Executive Director of North East Finance. Bill also advises several early-stage life science companies on strategy and finance and works with Ascendant Corporate Finance on specialist life sciences and fund management mandates. Previously, he was Director of Company Creation at Edinburgh BioQuarter and a Founder Director of its successor Sunergos Innovations. Prior to BioQuarter, he established Scottish Widow’s Investment Partnership’s highly successful life sciences venture capital fund and gained board experience in the UK, Europe and US.

15.45                  Closing remarks

Michelle Kinnaird

Investment Director

The Scottish Investment Bank

Michelle Kinnaird is the Investment Director in The Scottish Investment Bank (SIB), the investment arm of Scotland’s main economic development agency, Scottish Enterprise’s (SE), working in partnership with Highland and Islands Enterprise.

SIB ‘s role is to grow Scotland’s private sector funding market, ensuring both early stage and established SME’s with growth and exporting potential have adequate access to growth capital to reach their full potential.

SIB manages three funds – the Scottish Co-Investment Fund, the Scottish Venture Fund and the Renewable Energy Investment Fund; has invested in two externally managed funds; Epidarex Capital’s life sciences fund and the Scottish Loan Fund (now closed to new investments), which is privately managed by Maven Capital Partners and has developed a new funding mechanism in partnership with the European Investment Fund – the Scottish-European Growth Co-Investment Programme.

Michelle leads a team responsible for executing SE’s Investment transactions including SIB’s range of equity funds, is responsible for SE’s Scottish Loan Fund and European Investment Fund interest, the Renewable Energy Investment Fund and SIB’s Finance & Reporting Team. She has been the lead for SE in the establishment of the the Scottish-European Growth Co-Investment Programme.

 

 

In partnership with

BIA Annual Supporters

Register